Latest Content

Long-Term Postsurgical ADT May Reduce Prostate Cancer Metastasis Risk

June 4th 2024, 7:00pm

By Alex Biese

Article

Two years of postsurgical androgen deprivation therapy resulted in a 10-year metastasis-free survival rate of nearly 80%.

My Hereditary Breast Cancer Story

June 4th 2024, 5:03pm

By Sue McCarthy

Article

I believe I have hereditary cancer, especially after my daughter was approved to receive genetic testing for breast cancer.

Dato-DXd Improves Antitumor Intracranial Responses in NSCLC Subgroups

June 4th 2024, 3:06pm

By Kristie L. Kahl

Article

Dato-DXd was efficacious in patients with non-small cell lung cancer with brain metastases who have certain gene alterations, a phase 2 study showed.

Vaccine-Based Combo Shows Disease Control in CRC

June 4th 2024, 1:00pm

By Russ Conroy

Article

PolyPEPI1018 may boost the efficacy of Tecentriq in certain patients with colorectal cancer.

Belamaf Regimen Improves Progression-Free Survival in Myeloma

June 3rd 2024, 9:00pm

By Silas Inman

Article

Belamaf plus bortezomib and dexamethasone lengthened the time patients with relapsed or refractory myeloma lived before their disease got worse.

Bile Duct Cancer Continues to Respond to Zanidatamab, Per Longer Follow-Up

June 3rd 2024, 9:00pm

By Gina Mauro

Article

Zanidatamab continued to lead to responses and improved overall survival in pretreated HER2-positive biliary tract cancer.

Reblozyl Continues to Improve MDS Transfusion Independence

June 3rd 2024, 7:00pm

By Brielle Benyon

Article

Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl.

Experiencing a Type of Breast Cancer Déjà Vu

June 3rd 2024, 5:00pm

By Bonnie Annis

Article

After a good friend told me about her recent diagnosis of breast cancer, I started experiencing a type of breast cancer déjà vu.

An Expert Breakdown of SurVaxM, the Novel Brain Cancer Vaccine

June 3rd 2024, 3:00pm

By Brielle Benyon

Video

SurVaxM, which is being studied in gliobastoma, targets a certain protein that is found on the brain cancer cells.

Safety Profile of Lower-Dose Oral Onureg Remains Consistent in Lower-Risk MDS

June 3rd 2024, 1:00pm

By Ashley Chan

Article

The safety profile of 200 milligrams and 300 milligrams of oral Ongureg were similar in patients with lower- to intermediate-risk MDS.

Enhertu Boosts PFS in Pretreated, HR-Positive, HER2-Low and -Ultralow Breast Cancer

June 2nd 2024, 7:00pm

By Chris Ryan

Article

Enhertu lengthened the time to progression in patients with HR-positive, HER2-low or -ultralow metastatic breast cancer.

Chemo, Targeted Drugs Extremely Efficacious in HER2-Positive Breast Cancer

June 2nd 2024, 5:00pm

By Brielle Benyon

Video

Presurgical paclitaxel, Herceptin and Perjeta showed “incredible efficacy” in treatment of HER2-positive breast cancer.

Perioperative Chemo Shows Longer Survival in Esophageal Cancer

June 2nd 2024, 12:08pm

By Kyle Doherty

Article

Perioperative chemotherapy with chemotherapy led to improved survival outcomes versus neoadjuvant chemoradiation in resectable esophageal cancer.

Blenrep Combo Lengthens Time to Progression in Relapsed, Refractory Myeloma

June 2nd 2024, 12:02pm

By Russ Conroy

Article

Blenrep, Pomalyst and dexamethasone improved progression-free survival compared to Velcade, Pomalyst and dexamethasone in patients with relapsed/refractory myeloma.

Neoadjuvant Opdivo Plus Yervoy Provides ‘Excellent Responses’ in Stage 3 Melanoma

June 2nd 2024, 12:00pm

By Silas Inman

Article

Opdivo plus Yervoy in the neoadjuvant setting reduced the risk for recurrence, progression or death, potentially offering patients with stage 3 melanoma a new standard of care.